Literature DB >> 4035587

Teratogen update: clinical aspects of thalidomide embryopathy--a continuing preoccupation.

C G Newman.   

Abstract

There is much misinformation in the medical community regarding the thalidomide syndrome. Some physicians and scientists are unaware of the fact that organs other than the limbs were frequently affected. Some believe that thalidomide could produce any type of limb reduction defect. Most were aware of the very narrow period of early organogenesis during which the thalidomide-type malformations could be produced. Important features include the fact that limb reduction defects were primarily preaxial, included concomitant girdle hypoplasia when limb reductions were severe, were almost universally bilateral and did not include distal transverse-type defects often called "hemimelia". While it can be said that some spontaneous (non-thalidomide) malformations can mimic the thalidomide syndrome, it can also be said that many limb reduction defects can be determined not to have been produced by thalidomide. The risks of the various defects can be estimated following exposure, with most certainty for limb defects, with less certainty for other defects. Many defects were not associated with exposure to thalidomide such as cleft lip and severe mental retardation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4035587     DOI: 10.1002/tera.1420320118

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  8 in total

1.  Recognition of thalidomide defects.

Authors:  R W Smithells; C G Newman
Journal:  J Med Genet       Date:  1992-10       Impact factor: 6.318

Review 2.  Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus.

Authors:  M T Miller
Journal:  Trans Am Ophthalmol Soc       Date:  1991

3.  Thrombocytopenia-absent radius syndrome: a clinical genetic study.

Authors:  K L Greenhalgh; R T Howell; A Bottani; P J Ancliff; H G Brunner; C C Verschuuren-Bemelmans; E Vernon; K W Brown; R A Newbury-Ecob
Journal:  J Med Genet       Date:  2002-12       Impact factor: 6.318

4.  Robotic assisted radical prostatectomy for localised prostate cancer in thalidomide generation.

Authors:  Venkata Ramana Murthy Kusuma; Annelisse Ashton; Dimitrios Moschanos; Krishna Patil; Matthew Perry
Journal:  J Robot Surg       Date:  2017-08-28

5.  Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation.

Authors:  Vaibhav Shinde; Stefanie Klima; Perumal Srinivasan Sureshkumar; Kesavan Meganathan; Smita Jagtap; Eugen Rempel; Jörg Rahnenführer; Jan Georg Hengstler; Tanja Waldmann; Jürgen Hescheler; Marcel Leist; Agapios Sachinidis
Journal:  J Vis Exp       Date:  2015-06-17       Impact factor: 1.355

Review 6.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 7.  Thalidomide-induced teratogenesis: history and mechanisms.

Authors:  Neil Vargesson
Journal:  Birth Defects Res C Embryo Today       Date:  2015-06-04

8.  First trimester COVID-19 and the risk of major congenital malformations-International Registry of Coronavirus Exposure in Pregnancy.

Authors:  Sonia Hernández-Díaz; Louisa H Smith; Diego F Wyszynski; Sonja A Rasmussen
Journal:  Birth Defects Res       Date:  2022-08-05       Impact factor: 2.661

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.